2011至2019年美国脆性骨折后抗骨质疏松药物使用趋势
本研究基于PearlDiver患者记录数据库,纳入2011至2019年65岁以上脆性骨折患者,评估骨折后1年内使用14种最常用抗骨质疏松药物的治疗率。结果显示总体治疗率为8.01%,髋部骨折后为6.87%、上肢骨折后为6.71%、椎体压缩性骨折后为14.38%;2011至2018年总体治疗率无变化(p=0.32),仅椎体压缩性骨折治疗率上升(p=0.048)。
要点
- 脆性骨折后1年内抗骨质疏松药物治疗总体治疗率仅8.01%。
- 椎体压缩性骨折治疗率最高(14.38%),髋部骨折最低(6.87%)。
- 双膦酸盐是最常用药物类别,其和地舒单抗使用增加,降钙素使用减少。
核心结论
- 脆性骨折后骨质疏松治疗总体治疗率低,且过去十年内治疗率无变化。
- 作者认为需要为管理这些患者的提供者施加更多资源和干预以应对骨质疏松流行。
研究设计与样本
- 研究利用PearlDiver患者记录数据库识别2011至2019年65岁以上脆性骨折患者。
- 骨质疏松治疗率定义为脆性骨折后1年内处方14种最常用抗骨质疏松药物中任何一种的比率。
- 脆性骨折按类型亚分类,治疗进一步按患者人口学特征(年龄和性别)和药物类型分层。
主要发现
- 总体骨质疏松治疗率为8.01%,髋部骨折后为6.87%,上肢骨折后为6.71%,椎体压缩性骨折后为14.38%。
- 2011至2018年间总体脆性骨折治疗率无变化(p=0.32)。
- 分析的三种骨折类别中,仅椎体压缩性骨折治疗率上升(p=0.048)。
- 椎体压缩性骨折患者的骨质疏松治疗在65-74岁患者(p<0.05)和男性患者(p=0.013)中增加。
- 上肢骨折患者的治疗在70-74岁患者中增加(p=0.038)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: The purpose of this study was to determine whether there has been any change in osteoporosis treatment following primary fragility fractures and what agents were being given. The study found an overall low utilization rate with no difference in treatment utilization from 2011 to 2019. PURPOSE: The aim of this study is to describe trends in the utilization of anti-osteoporotic medication after fragility fracture, including changes in the specific types of medications prescribed. METHODS: Patients older than 65 with fragility fractures sustained from 2011 to 2019 were identified in the PearlDiver Patient Records Database. Osteoporosis treatment rate was defined as the rate at which patients were prescribed any of the fourteen most used anti-osteoporotic medications within 1 year of fragility fracture. Fragility fractures were subcategorized by type. Treatment of fragility fractures was further stratified by patient demographics (age and gender) and medication type. RESULTS: This study showed an overall osteoporosis treatment rate of 8.01%, with treatment rates of 6.87% following hip fractures, 6.71% following upper extremity fractures, and 14.38% following vertebral compression fractures (VCF). From 2011 to 2018, there was no change in the overall fragility fracture treatment rate (p = 0.32). Of the three fracture categories analyzed, only the treatment rate for VCFs increased (p = 0.048). Osteoporosis treatment in patients with VCF increased among patients 65-74 years old (p < 0.05) and male patients (p = 0.013). Treatment in patients with upper extremity fractures increased among patients 70-74 years old (p = 0.038). Bisphosphonates were the most frequently prescribed class of medications. Bisphosphonates and denosumab increased in utilization (p = 0.049 and p < 0.001 respectively) while calcitonin utilization decreased (p < 0.001). CONCLUSION: Besides the overall low utilization rate of osteoporosis treatment in patients following fragility fractures, there has been no change in the treatment utilization rate within the past decade. More resources and interventions need to be enforced for all providers managing these patients if we are ever to address the osteoporosis epidemic.
引用
- Agarwal AR, Cohen JS, Jorgensen A, et al. Trends in anti-osteoporotic medication utilization following fragility fracture in the USA from 2011 to 2019. Osteoporos Int. 2022. PMID: 36462054. doi:10.1007/s00198-022-06622-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。